Innate Pharma SA, a developer of immunotherapies for cancer, has appointed Jonathan Dickinson as chief executive officer and chairman of the executive board, effective 1 November. He succeeds interim CEO Hervé Brailly, co-founder of the company, and will drive the advancement of Innate's antibodys pipeline and position the company for the next phase of growth.
Innate Pharma announced the appointment on 14 October 2024.
Copyright 2024 Evernow Publishing Ltd